Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes...
(Thomson Reuters ONE) -
Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce
Strategic Partnership to Establish Joint Technology Laboratory to Develop
Control Processes for the Manufacture of CAR-T and Stem Cell Therapies
SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 (GLOBE NEWSWIRE)
-- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a
leading clinical-stage biopharmaceutical firm engaged in the development of
immunotherapies for cancer and stem cell therapies for degenerative diseases and
GE Healthcare Life Sciences China, today announced that they have established a
strategic research collaboration to co-develop certain high-quality industrial
control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell
manufacturing. In connection with the collaboration, a joint laboratory within
CBMG's new Shanghai Zhangjiang GMP-facility will be established and dedicated to
the joint research and development of a functionally integrated and automated
immunotherapy cell preparation system.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab5bc905-b526-4e86-98bd-
c96e306b5796
CBMG and GE Healthcare Life Sciences China plan to develop state-of-the-art
automated CAR-T and stem cell manufacturing capabilities that build upon the
accreditation of CBMG's GMP facilities in Shanghai, Wuxi and Beijing. The co-
development activity will aim to standardize the delivery of cell manufacturing
to potentially improve throughput, alleviate cost burdens and to minimize
variability in cell production, which may increase the availability of
engineered cells upon commercialization.
This partnership combines CBMG's scientific expertise in the manufacturing of
CAR-T and stem cell production in China and GE Healthcare's renowned expertise
in the design and development of innovative manufacturing technologies for the
biopharmaceutical industry.
Recently, CBMG announced that its new Zhangjiang facility, together with an
expanded Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square
feet for development and production. This will enable CBMG to conduct
simultaneous clinical trials for multiple CAR-T and stem cell product
candidates. At full production volumes, these facilities could support the
treatment of up to 10,000 cancer patients and 10,000 knee osteoarthritis
patients per year.
"GE Healthcare's selection of our facility to serve as their showcase site in
China, credits our GMP stature and capabilities. Our team of scientists has
spent years refining our manufacturing process to become one of the very few
cell therapy companies with fully in-house integrated chemistry, manufacturing,
and controls (CMC) processes for clinical grade CAR-T cells, plasmid and viral
vectors bank production. We understand that one of the impending barriers to
adoption of immuno-oncology and stem cell therapies is the logistics in
manufacturing and we look to take an expanded role both domestically and
potentially globally. We are pleased to be in a strategic partnership with GE
Healthcare and look forward to showcasing our facilities and the mutual benefit
this joint laboratory will bring," commented Tony Liu, Chief Executive Officer,
CBMG.
"Cell therapy as an industry continues to refine and evolve in China with vast
potential to change the ways various diseases are treated. GE continues
investing in technologies and services aimed at the thriving cell therapy
industry with a firm commitment of making these promising therapies accessible
through successful industrialization. We are pleased to partner with CBMG, a
leader in CAR-T and stem cell development in China and to take advantage of
their excellent CMC cell production capabilities. Collaboration with ambitious
partners like CBMG who share our vision is necessary for advancing innovation
and delivering comprehensive manufacturing solutions for cell and regenerative
medicines," said Li Qing, General Manager, GE Healthcare Life Sciences, Greater
China.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. We conduct
immuno-oncology and stem cell clinical trials in China using products from our
integrated GMP laboratory. Our GMP facilities in China, consisting of twelve
independent cell production lines, are designed and managed according to both
China and U.S. GMP standards. CBMG recently commenced two Phase I human
clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell
Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma
(DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM (CBMG's
"Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the
treatment of Knee Osteoarthritis (KOA). CBMG was also recently awarded $2.29
million from the California Institute for Regenerative Medicine (CIRM) to
support pre-clinical studies of AlloJoinTM for Knee Osteoarthritis in the United
States. To learn more about CBMG, please visit www.cellbiomedgroup.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to
meet the demand for increased access, enhanced quality and more affordable
healthcare around the world. GE (NYSE:GE) works on things that matter - great
people and technologies taking on tough challenges. From medical imaging,
software & IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance improvement
solutions, GE Healthcare helps medical professionals deliver great healthcare to
their patients. For more information about GE Healthcare, visit our website
at www.gehealthcare.com.
Forward-Looking Statements
This press release contains forward-looking statements-including descriptions of
plans, strategies, trends, specific activities, investments and other non-
historical facts-as defined by the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking information is
inherently uncertain, and actual results could differ materially from those
anticipated due to a number of factors, which include risks inherent in doing
business, trends affecting the global economy (including the devaluation of the
RMB by China in August 2015), and other risks detailed in CBMG's reports filed
with the Securities and Exchange Commission, quarterly reports on form 10-Q,
current reports on form 8-K and annual reports on form 10-K. Forward-looking
statements may be identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," "continue" or similar terms or their
negations. Although CBMG believes the expectations reflected in the forward-
looking statements are reasonable, they cannot guarantee that future results,
levels of activity, performance or achievements will be obtained. CBMG does not
have any obligation to update these forward-looking statements other than as
required by law.
The photo is also available at Newscom, www.newscom.com, and via AP
PhotoExpress.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly(at)cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711
vivian.chen(at)citigatedr.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cellular Biomedicine Group Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2017 - 14:48 Uhr
Sprache: Deutsch
News-ID 535479
Anzahl Zeichen: 8907
contact information:
Town:
Shanghai
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 579 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes..."
steht unter der journalistisch-redaktionellen Verantwortung von
Cellular Biomedicine Group Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
